Researchers explore the risks of cardiovascular and cerebrovascular events following vaccination against the COVID-19.
Argenx scraps program in skin autoimmune disease after Vyvgart Hytrulo flunks another PhIII trial
Argenx’s autoimmune disease drug Vyvgart Hytrulo flunked its second late-stage trial in as many months, and the company is abandoning the indication altogether. The Dutch